Risk of endometrial carcinoma associated with BRCA mutation.

OBJECTIVE Inherited mutations in the BRCA1 or BRCA2 genes are associated with a greatly increased lifetime risk of breast and ovarian cancers and a modestly increased risk of several other cancer types. Several case reports of endometrial carcinoma in women with a BRCA mutation have led to speculation regarding the effect of these genes on the risk of endometrial cancer. The purpose of this study was to test the hypothesis that germline mutation of a BRCA gene is associated with an increased risk of endometrial carcinoma. METHODS A retrospective cohort of 199 consecutive Ashkenazi Jewish patients with endometrial carcinoma was identified from a 12-year period at this institution. All were genotyped for the three BRCA founder mutations (185delAG and 5382insC in BRCA1 and 6174delT in BRCA2) that exist in this population, and the case frequency was compared to the known population frequency of these mutations. Additionally, endometrial carcinomas occurring in patients with BRCA mutations were assessed for somatic loss of the wild-type BRCA allele. RESULTS Germline BRCA mutations were identified in 3 (1 in BRCA1 and two in BRCA2) of 199 (1.5%) patients, compared to a frequency of 2.0% in this population generally. A relative risk of endometrial carcinoma associated with BRCA mutation, as estimated by the odds ratio, was calculated as 0.75 (95% CI = 0.24--2.34; P = 0.6). Loss of the wild-type BRCA allele was observed in two of three tumors associated with a BRCA mutation. CONCLUSIONS For individuals with a germline BRCA mutation, the lifetime risk of endometrial carcinoma is not increased.

[1]  A. Fyles,et al.  Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? , 2000, Gynecologic oncology.

[2]  G. Wiesner,et al.  Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. , 2000, Gynecologic oncology.

[3]  D. Fishman,et al.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. , 2000, American journal of human genetics.

[4]  E. Levy-Lahad,et al.  Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. , 1999, Gynecologic oncology.

[5]  M. Morgan,et al.  Allelotype analysis of uterine leiomyoma: Localization of a potential tumor suppressor gene to a 4‐cM region of chromosome 7q , 1998, Molecular carcinogenesis.

[6]  W. Strauss.  Preparation of Genomic DNA from Mammalian Tissue , 1998, Current protocols in molecular biology.

[7]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[8]  A. Shih,et al.  Mutational analysis of the BRCA1 tumor suppressor gene in endometrial carcinoma. , 1997, Gynecologic oncology.

[9]  D E Goldgar,et al.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. , 1997, American journal of human genetics.

[10]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[11]  H. Mefford,et al.  BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. , 1997, American journal of human genetics.

[12]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[13]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[14]  Kenneth Offit,et al.  The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% , 1996, Nature Genetics.

[15]  D. Easton,et al.  High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. , 1996, Cancer research.

[16]  J. Boyd,et al.  Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome , 1996, Cancer.

[17]  J. Eyfjörd,et al.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes , 1996, Nature Genetics.

[18]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[19]  H. Sasaki,et al.  Allelotype of endometrial carcinoma. , 1994, Cancer research.

[20]  P. V. van Diest,et al.  Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. , 2000, Gynecologic oncology.

[21]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[22]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.